The Neuropsychopharmacology and Toxicology of 3,4‐methylenedioxy‐N‐ethyl‐amphetamine (MDEA)
Roland W. Freudenmann, Manfred Spitzer
CNS Drug Reviews June 1, 2004 DOI: 10.1111/j.1527-3458.2004.tb00007.x (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | MDMA |
| Keywords | Amphetamine Methylenedioxy Pharmacology |
| Citations | 41 |
| Key findings | MDEA is pharmacologically similar to MDMA, and its serotonergic neurotoxicity in humans remains uncertain due to polysubstance use in ecstasy users. |
Abstract
ABSTRACT This paper reviews the pharmacology and toxicology of 3,4‐methylenedioxy‐N‐ethyl‐amphetamine (MDEA, “eve”). MDEA is a ring‐substituted amphetamine (RSA) like MDMA, its well known N‐methyl analog. Both have become very popular substances of abuse in the techno‐ and house‐music scene. They can evoke psychomotor stimulation, mild alterations of perception, sensations of closeness and a positive emotional state as well as sympathomimetic physical effects. At present, the name “ecstasy” is no longer used only for MDMA, but for the whole group of RSAs (MDA, MDMA, MDEA and MBDB) as they are chemically and pharmacologically nearly identical; moreover, many ecstasy pills contain mixtures of the RSAs. Hence, for a selective review on MDEA, it is crucial to strictly differentiate between: 1) street and chemical names, and 2) studies with or without chemically defined substances. In order to present MDEA‐specific information, the pharmacodynamics and kinetics are described on the basis of MDEA challenge studies in animals and humans. In the toxicology section, we present a collection of case reports on fatalities where MDEA was toxicologically confirmed. On the question of serotonergic neurotoxicity and possible long‐term consequences, however, MDEA‐specific information is available from animal studies only. The neurotoxic potential of MDEA in humans is difficult to estimate, as ecstasy users do not consume pure substances. For future research, challenge studies in animals using dosing regimens adapted to human consumption patterns are needed. Such challenge studies should directly compare individual RSAs. They will represent the most viable and fruitful approach to the resolution of the highly controversial issues of serotonergic neurotoxicity and its functional consequences.
Comparable studies
Other narrative reviews on MDMA, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Human Pharmacology of MDMA | 2004 | Review | |
| Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research | 2001 | Review | |
| 3,4‐Methylenedioxymethamphetamine (MDMA, “Ecstasy”): pharmacology and toxicology in animals and humans | 1994 | Review | |
| (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals | 2000 | Review | |
| Amphetamine toxicities | 2010 | Review |
Citations in the library
Cited by 13
- The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents* Addiction July 8, 2006
- Pill content, dose and resulting plasma concentrations of 3,4‐methylendioxymethamphetamine (MDMA) in recreational ‘ecstasy’ users Addiction February 14, 2011
- Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy Journal of Psychopharmacology September 10, 2020
- Enantioselectivity in the Methylation of the Catecholic Phase I Metabolites of Methylenedioxy Designer Drugs and Their Capability To Inhibit Catechol-O-methyltransferase-Catalyzed Dopamine 3-Methylation Chemical Research in Toxicology May 22, 2009
- Comparative potencies of 3,4‐methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5‐HT transport in mammalian cell lines British Journal of Pharmacology September 24, 2007
and 8 more in the library
Cites 62
- Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin Synapse 2000
- Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens Journal of Psychoactive Drugs October 1, 1986
- Hallucinogenic Amphetamine Selectively Destroys Brain Serotonin Nerve Terminals Science September 6, 1985
- Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research Human Psychopharmacology: Clinical and Experimental December 1, 2001
- Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) Journal of Neurology, Neurosurgery, and Psychiatry June 1, 2000
and 57 more in the library